Clinical Pharmacy Services in Ambulatory Oncology: An Environmental Scan of the Canadian Practice Landscape

被引：3
作者：
Tibensky, Bryanna [1 ,2 ]
Hutton, Lauren [3 ,4 ]
Wentzell, Jason [2 ,5 ]
LeBlanc, Michael [6 ]
Edwards, Scott [7 ,8 ]
McFarlane, Thomas [2 ]
机构：
[1] Univ Waterloo, Ctr Family Med Family Hlth Team, Waterloo, ON, Canada
[2] Univ Waterloo, Sch Pharm, Waterloo, ON, Canada
[3] Nova Scotia Hlth, Halifax, NS, Canada
[4] Beatrice Hunter Canc Res Inst, Halifax, NS, Canada
[5] Extend Pharm & Extend Hlth Solut, Ottawa, ON, Canada
[6] Horizon Hlth Network, New Brunswick, NJ USA
[7] Eastern Hlth, St John, NL, Canada
[8] Mem Univ St Johns, St John, NL, Canada
来源：
CANADIAN JOURNAL OF HOSPITAL PHARMACY | 2022年 / 75卷 / 04期
关键词：
clinical pharmacy key performance indicator; key performance indicator; ambulatory oncology; oncology pharmacy; outpatient oncology; Canada;
D O I：
10.4212/cjhp.3208
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Background: Canadian clinical pharmacy key performance indicators (cpKPIs) have been developed for inpatient hospital practice but are not established for ambulatory oncology. This study represents the first step in developing cpKPIs for ambulatory oncology.Objectives: To describe the current landscape of pharmacy services in ambulatory oncology in Canada and to identify perspectives related to the development and implementation of cpKPIs in this practice setting.Methods: In this national cross-sectional study, a web-based questionnaire was distributed to pharmacists working in ambulatory oncology settings. Potential participants who self-identified as pharmacists practising in an ambulatory oncology setting were eligible. Survey questions focused on participants' demographic characteristics, oncology pharmacy services provided, metrics captured, and pharmacists' perceptions of cpKPIs. All data were analyzed using descriptive statistics.Results: A total of 44 responses were received, with most respondents practising in community hospitals in British Columbia, Ontario, and Atlantic Canada. The services most commonly provided were chemotherapy order verification, laboratory monitoring, identification and resolution of drug therapy problems, and counselling on anticancer medications. Twenty-six of the 44 respondents (59%) indicated that performance metrics or patient outcomes were tracked at their respective institutions, with none being universally captured. Overall, 43 (98%) of the respondents favoured the development of cpKPIs for ambulatory oncology practice.Conclusions: Despite growing patient care needs in ambulatory oncology, there is significant heterogeneity in the scope of pharmacy services offered and the outcomes used to qualify their impact within this setting across Canada. This study demonstrates a clear need for national consensus cpKPIs to inform pharmacy resource utilization and patient -centred quality improvement initiatives.
引用
收藏
页码：259 / 266
页数：8
相关论文
共 36 条
  • [21] Ribed A, Romero-Jimenez RM, Escudero-Vilaplana V, Iglesias-Peinado I, Herranz-Alonso A, Codina C, Et al., Pharmaceutical care program for onco-hematologic outpatients: safety, efficiency and patient satisfaction, Int J Clin Pharm, 38, 2, pp. 280-288, (2016)
  • [22] Wong SF, Bounthavong M, Nguyen CP, Chen T., Outcome assessments and cost avoidance of an oral chemotherapy management clinic, J Natl Compr Cancer Netw, 14, 3, pp. 279-285, (2016)
  • [23] Escudero-Vilaplana V, Ribed A, Romero-Jimenez RM, Herranz-Alonso A, Sanjurjo-Saez M., Pharmacotherapy follow-up of key points in the safety of oral antineoplastic agents, Eur J Cancer Care (Engl), 26, 3, (2017)
  • [24] Lopez-Martin C, Garrido Siles M, Alcaide-Garcia J, Faus Felipe V., Role of clinical pharmacists to prevent drug interactions in cancer outpatients: a single-centre experience, Int J Clin Pharm, 36, 6, pp. 1251-1259, (2014)
  • [25] Caracuel F, Banos U, Herrera MD, Ramirez G, Munoz N., Influence of pharmaceutical care on the delayed emesis associated with chemotherapy, Int J Clin Pharm, 36, 2, pp. 287-290, (2014)
  • [26] Gagnon L, Fairchild A, Pituskin E, Dutka J, Chambers C., Optimizing pain relief in a specialized outpatient palliative radiotherapy clinic: contributions of a clinical pharmacist, J Oncol Pharm Pract, 18, 1, pp. 76-83, (2012)
  • [27] Muluneh B, Schneider M, Faso A, Amerine L, Daniels R, Crisp B, Et al., Improved adherence rates and clinical outcomes of an integrated, closed-loop, pharmacist-led oral chemotherapy management program, J Oncol Pract, 14, 6, pp. e324-e334, (2018)
  • [28] Simons S, Ringsdorf S, Braun M, Mey UJ, Schwindt PF, Ko YD, Et al., Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care, Support Care Cancer, 19, 7, pp. 1009-1018, (2011)
  • [29] Read H, Ladds S, Rhodes B, Brown D, Portlock J., The impact of a supplementary medication review and counselling service within the oncology outpatient setting, Br J Cancer, 96, 5, pp. 744-751, (2007)
  • [30] Krikorian S, Pories S, Tataronis G, Caughey T, Chervinsky K, Lotz M, Et al., Adherence to oral chemotherapy: challenges and opportunities, J Oncol Pharm Pract, 25, 7, pp. 1590-1598, (2019)
1234